ASKER Stock Analysis: Asker Healthcare | ST
Medical Distribution | ST, Sweden | Market Cap: 32.845m SEK | 12M Return: -30.9% | SE0024171458 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 32.8M
Warnings
Tailwinds
Seasonality 1.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Asker Healthcare Group is a Sweden-based medical distributor supplying healthcare providers with medical devices, equipment and consumables across areas including surgery, diagnostics, wound care, mobility and rehabilitation. Its portfolio also includes in-house disposable medical supply brands Evercare, Selefa and Embr.
The company combines product distribution with care-related services, rentals and support for patients and healthcare organizations. It operates across Northern, Western and Central Europe; medical distributors typically help healthcare providers source products from multiple manufacturers.
- Acquisitions expand European reach but raise integration and debt risks
- Own-brand medical consumables support margins amid distributor price competition
- Public healthcare budgets and hospital demand drive sales across Europe
| Net Income: 594.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.44 > 1.0 |
| NWC/Revenue: 7.95% < 20% (prev 13.69%; Δ -5.74% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.64b > Net Income 594.0m |
| Net Debt (6.16b) to EBITDA (1.60b): 3.84 < 3 |
| Current Ratio: 1.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (383.0m) vs 12m ago 18.26% < -2% |
| Gross Margin: 38.39% > 18% (prev 39.12%; Δ -0.73% > 0.5%) |
| Asset Turnover: 108.3% > 50% (prev 105.6%; Δ 2.69% > 0%) |
| Interest Coverage Ratio: 1.58 > 6 (EBIT TTM 720.0m / Interest Expense TTM 457.0m) |
| A: 0.08 (Total Current Assets 5.85b - Total Current Liabilities 4.48b) / Total Assets 17.8b |
| B: 0.12 (Retained Earnings 2.15b / Total Assets 17.8b) |
| C: 0.05 (EBIT TTM 720.0m / Avg Total Assets 16.0b) |
| D: 0.63 (Book Value of Equity 6.83b / Total Liabilities 10.9b) |
| Altman-Z'' = 1.86 = BBB |
| DSRI: 1.05 (Receivables 2.73b/2.24b, Revenue 17.3b/15.0b) |
| GMI: 1.02 (GM 39.12% / 38.39%) |
| AQI: 1.01 (AQ_t 0.56 / AQ_t-1 0.56) |
| SGI: 1.15 (Revenue 17.3b / 15.0b) |
| TATA: -0.06 (NI 594.0m - CFO 1.64b) / TA 17.8b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of October 31, 2026, the stock is trading at SEK 71.25 with a total of 217,533 shares traded. Over the past week, the price has changed by -4.69%, over one month by -4.13%, over three months by +15.45% and over the past year by -30.87%.
Current recommended Stop Loss: 68.10 (which is 4.4% or 1.5 ATR below the current price).
Asker Healthcare has no consensus analysts rating.
P/E Trailing = 54.968
P/S = 1.8972
P/B = 4.6107
Revenue TTM = 17.3b SEK
EBIT TTM = 720.0m SEK
EBITDA TTM = 1.60b SEK
Long Term Debt = 4.24b SEK (from longTermDebt, last quarter)
Short Term Debt = 1.01b SEK (from shortTermDebt, last quarter)
Debt = 7.11b SEK (from shortLongTermDebtTotal, last quarter) + Leases 1.09b
Net Debt = 6.16b SEK (calculated: Debt 7.11b - CCE 945.0m)
Enterprise Value = 39.0b SEK (32.8b + Debt 7.11b - CCE 945.0m)
Interest Coverage Ratio = 1.58 (Ebit TTM 720.0m / Interest Expense TTM 457.0m)
EV/FCF = 38.32x (Enterprise Value 39.0b / FCF TTM 1.02b)
FCF Yield = 2.61% (FCF TTM 1.02b / Enterprise Value 39.0b)
FCF Margin = 5.88% (FCF TTM 1.02b / Revenue TTM 17.3b)
Net Margin = 3.43% (Net Income TTM 594.0m / Revenue TTM 17.3b)
Gross Margin = 38.39% ((Revenue TTM 17.3b - Cost of Revenue TTM 10.7b) / Revenue TTM)
Gross Margin QoQ = 35.94% (prev 41.25%)
Tobins Q-Ratio = 2.20 (Enterprise Value 39.0b / Total Assets 17.8b)
Interest Expense / Debt = 6.43% (Interest Expense 457.0m / Debt 7.11b)
Taxrate = 21.74% (170.0m / 782.0m)
NOPAT = 563.5m (EBIT 720.0m * (1 - 21.74%))
Current Ratio = 1.31 (Total Current Assets 5.85b / Total Current Liabilities 4.48b)
Debt / Equity = 1.04 (Debt 7.11b / totalStockholderEquity, last quarter 6.83b)
Debt / EBITDA = 3.84 (Net Debt 6.16b / EBITDA 1.60b)
Debt / FCF = 6.05 (Net Debt 6.16b / FCF TTM 1.02b)
Total Stockholder Equity = 6.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.71% (Net Income 594.0m / Total Assets 17.8b)
RoE = 9.05% (Net Income TTM 594.0m / Total Stockholder Equity 6.56b)
RoCE = 6.66% (EBIT 720.0m / Capital Employed (Equity 6.56b + L.T.Debt 4.24b))
RoIC = 4.20% (NOPAT 563.5m / Invested Capital 13.4b)
WACC = 8.41% (E(32.8b)/V(40.0b) * Re(9.14%) + D(7.11b)/V(40.0b) * Rd(6.43%) * (1-Tc(0.22)))
Discount Rate = 9.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 7.14 | Cagr: 0.0%
[DCF] Terminal Value 77.78% ; FCFF base≈962.4m ; Y1≈1.10b ; Y5≈1.62b
[DCF] Fair Price = 47.04 (EV 24.2b - Net Debt 6.16b = Equity 18.0b / Shares 383.0m; r=8.41% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 100.00 | Revenue CAGR: 11.71% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=2.97 | Chg30d=+2.35% | Revisions=+29% | GrowthEPS=+68.4% | GrowthRev=+14.4%
EPS next Year (2027-12-31): EPS=3.43 | Chg30d=+0.70% | Revisions=+0% | GrowthEPS=+15.3% | GrowthRev=+7.4%
[Analyst] Revisions Ratio: +18% (up=5, down=3)